血浆多不饱和脂肪酸水平与不良肾脏结局的关系
在UK Biobank前瞻性队列中,无CKD者(73,419人)血浆PUFA及4种组分水平越高,新发CKD风险越低;CKD患者(6,735人)中仅DHA水平较高与需肾脏替代治疗的肾衰竭风险降低相关。
要点
- 无CKD人群中,血浆PUFA及omega-3、omega-6、DHA、亚油酸水平较高均与新发CKD风险降低相关。
- CKD患者中总PUFA与KFRT无关,仅DHA水平较高与KFRT风险降低相关。
- 研究为观察性设计,不能推断因果关系。
核心结论
- 无CKD者血浆PUFA水平及全部4种PUFA组分较高与新发CKD风险降低相关。
- CKD患者中仅omega-3组分DHA较高与KFRT风险降低相关。
研究设计与样本
- 前瞻性观察性队列研究,数据来自UK Biobank,PUFA水平于2007至2010年测定。
- 队列1为73,419名无CKD参与者,队列2为6,735名CKD参与者。
主要发现
- 队列1随访841,007人年(中位11.9年),4.5%参与者发生新发CKD,发病率为39.1/10,000人年。
- 队列1中,相比第1四分位,第2、3、4四分位血浆PUFA水平的调整病因特异性风险比分别为0.83(95%CI 0.75-0.92)、0.85(95%CI 0.76-0.96)、0.71(95%CI 0.62-0.82)。
- 队列1中该负相关在所有PUFA类型中一致观察到大。
- 队列2中总PUFA水平与KFRT无关,但DHA水平较高与KFRT风险降低相关。
临床怎么用
- 在无CKD人群中,较高血浆PUFA水平与较低新发CKD风险相关,提示健康脂肪摄入可能有益。
- 在CKD患者中,DHA水平较高与较低KFRT风险相关,但总PUFA无关。
局限性
- 观察性设计不能确立因果关系。
- 结果对疾病严重程度较高人群的普遍性有限。
- 缺乏二十碳五烯酸(EPA)数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Many studies have reported polyunsaturated fatty acids (PUFA) as significant predictors of cardiovascular disease, but little is known about the relationship between PUFA levels and chronic kidney disease (CKD). This study explored this relationship among individuals with and without CKD. STUDY DESIGN: Prospective observational cohort study. SETTING & PARTICIPANTS: 73,419 participants without CKD (cohort 1) and 6,735 participants with CKD (cohort 2) in the UK Biobank Study, with PUFA levels measured between 2007 and 2010. EXPOSURE: Percentage of plasma PUFA, omega-3 fatty acid (FA), omega-6 FA, docosahexaenoic acid (DHA), and linoleic acid relative to total FA. OUTCOME: Incident CKD for cohort 1 and incident kidney failure requiring replacement therapy (KFRT) for cohort 2. ANALYTICAL APPROACH: Cox proportional hazards regression analyses, including a cause-specific competing risk model. RESULTS: In cohort 1, individuals with higher quartiles of plasma PUFA levels had healthier lifestyles and fewer comorbidities. During 841,007 person-years of follow-up (median 11.9 years), incident CKD occurred in 4.5% of participants (incidence rate, 39.1 per 10,000 person-years). For incident CKD in cohort 1, the adjusted cause-specific hazard ratios for quartiles 2, 3, and 4 were 0.83 (95% CI, 0.75-0.92), 0.85 (95% CI, 0.76-0.96), 0.71 (95% CI, 0.62-0.82), respectively, compared with quartile 1. This inverse relationship was consistently observed for all PUFA types. In cohort 2, although total PUFA levels were not associated with KFRT, higher PUFA subtype levels of DHA were associated with a lower risk of KFRT. LIMITATIONS: Observational design and limited generalizability to individuals with higher disease severity; no data on eicosapentaenoic acid. CONCLUSIONS: Among individuals without CKD, higher plasma PUFA levels and all 4 PUFA components were associated with a lower risk of incident CKD. In individuals with CKD, only the omega-3 component of PUFA, DHA, was associated with a lower risk of KFRT. PLAIN-LANGUAGE SUMMARY: Low amounts of polyunsaturated fatty acids (PUFA) in the blood are suspected of increasing the chances of heart disease, but it is not known whether the PUFA relates to kidney disease occurrence. In a large group without kidney disease in the United Kingdom, people with higher levels of PUFA in their blood tended to have a lower risk of developing kidney disease compared to those with lower PUFA levels. This relationship was consistently observed for all PUFA types. However, in the group with kidney disease, only higher levels of docosahexaenoic acid, a subtype of PUFAs, were associated with a lower risk of developing severe kidney problems that required kidney replacement therapy. These findings suggest that higher levels of PUFA, found in certain healthy fats, might protect against the development of kidney disease in the general population. As kidney function declines, only the docosahexaenoic acid, a subtype of PUFA, appears to be associated with preserved kidney function.
引用
- Koh HB, Kim HW, Joo YS, et al. Plasma Levels of Polyunsaturated Fatty Acids and Adverse Kidney Outcomes. Am J Kidney Dis. 2024. PMID: 38423161. doi:10.1053/j.ajkd.2023.12.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。